TLDR: The global artificial intelligence (AI) in biotechnology market, valued at approximately $3.8 billion in 2024, is forecast to surge to $11.4 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 20% from 2025 to 2030. This significant expansion is primarily fueled by AI’s transformative impact on accelerating drug discovery, optimizing clinical trials, and advancing diagnostics and genomic research.
The artificial intelligence (AI) in biotechnology market is on the cusp of unprecedented growth, with projections indicating a valuation of $11.4 billion by 2030. This represents a substantial increase from its $3.8 billion valuation in 2024, driven by a compound annual growth rate (CAGR) of 20% between 2025 and 2030. Other analyses suggest the market could reach $13.30 billion by 2032 with a CAGR of 19.13% (2025-2032), or even $18.76 billion by 2034 at a 19.04% CAGR (2025-2034).
AI’s pivotal role in revolutionizing the biotechnology sector is evident across multiple domains. It is dramatically accelerating drug discovery, streamlining complex clinical trials, and significantly enhancing diagnostics and genomic research. Key applications include target identification, protein structure prediction, preclinical trial simulations, and the development of personalized therapies. This integration of AI is enabling pharmaceutical and biotechnology companies to reduce trial durations, lower research and development (R&D) costs, and improve outcomes in precision medicine.
Leading the charge in this transformative era are companies such as Nvidia, Tempus AI Inc., Recursion Pharmaceuticals, Schrödinger Inc., and Sophia Genetics. These innovators are leveraging advanced AI techniques, including machine learning, generative artificial intelligence, and federated learning, to drive progress. For instance, Caris Life Sciences has utilized AI to profile over 849,000 cancer cases, generating an astounding 38 billion molecular markers to identify optimal patient therapies. In a notable development in April 2025, Plex Research partnered with Ginkgo Bioworks to employ AI for identifying new disease mechanisms, while Isomorphic Labs secured $600 million in May 2025 for next-generation drug design models.
Industry insights underscore the strategic importance of AI. A 2025 NVIDIA survey revealed that 83% of life science leaders anticipate AI will transform their industries within the next five years. This sentiment is echoed by significant investments and partnerships, such as AstraZeneca’s $5.2 billion deal with Chinese biotech firm CSPC in 2025 to co-develop chronic disease therapies using AI models. Furthermore, it is projected that by early 2025, over 60% of early-stage biotech pipelines will be leveraging AI.
Geographically, North America currently dominates the AI in biotechnology market, holding approximately 50% of the market share in 2024. This leadership is attributed to its mature healthcare infrastructure, substantial R&D investments, and high adoption rates of AI in drug development. The U.S. market alone was valued at $1.14 billion in 2024 and is expected to reach $4.24 billion by 2032. Meanwhile, the Asia Pacific region is anticipated to exhibit the fastest CAGR during the forecast period.
Also Read:
- Global Artificial Intelligence Market Poised for Significant Growth, Projected to Exceed $3.6 Trillion by 2034
- Generative AI Transforms Insurance Sector, Market Set for Exponential Growth
As the industry progresses, AI is not merely an enhancement but an integral component, redefining how biotech companies conduct research and develop solutions. While ethical and regulatory considerations, including U.S. export control regulations, remain crucial areas for ongoing attention, the undeniable momentum behind AI-driven biotechnology promises a future of accelerated innovation and improved healthcare outcomes.
